glp-1 elevated liver enzymes RAs for Treating Metabolic Dysfunction-Associated Steatosis Disease: From GLP-1 Discovery to FDA Approval: A Comprehensive Narrative Review semaglutide and elevated liver enzymes

A phase 2 randomised controlled trial published in the New England Journal of Medicine (2023) reported substantial weight loss and improvements in glycaemic parameters, though the trial was conducted in a closely monitored clinical setting with defined eligibility criteria

However, HGH doesnt act alone it requires sufficient nutritional intake and consistent training to be effective

In STEP 1 [1] , the largest trial with 1,961 participants [1] , patients receiving semaglutide 2.4 mg weekly achieved an average weight loss of 14.9% over 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021)

E.BrethauerS